[CAS NO. 1346704-33-3]  GSK343

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1346704-33-3]

Catalog
SLK-S7164
Brand
Selleck
CAS
1346704-33-3

DESCRIPTION [1346704-33-3]

Overview

MDLMFCD25563250
Molecular Weight541.69
Molecular FormulaC31H39N7O2
SMILESC(NCC1=C(CCC)C=C(C)NC1=O)(=O)C2=C3C(N(C(C)C)N=C3)=CC(=C2)C=4C=C(N=CC4)N5CCN(C)CC5

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM1.8461 mL9.2304 mL18.4607 mL
5 mM0.3692 mL1.8461 mL3.6921 mL
10 mM---
50 mM---

Description

GSK343 is a potent and selective inhibitor with of 4 nM in a cell-free assay, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases. GSK343 induces .

Features

A chemical probe for the SGC epigenetics initiative. Potential use in a variety of solid tumors.

Targets

EZH2 [1]
(Cell-free assay)
EZH1 [1]
(Cell-free assay)
4 nM240 nM

In vitro

GSK343 inhibits trimethylation of H3K27 (H3K27me3) with IC50 of 174 nM in HCC1806 breast cancer cells. GSK343 potently inhibits cell proliferation in breast cancer cells and prostate cancer cells, and the prostate cancer cell line LNCaP is the most sensitive to GSK343, with IC50 of 2.9 μM. GSK343 significantly suppresses the growth of EOC cells cultured in 3D matrigel extracellular matrix (ECM), which mimics the tumor microenvironment in vivo. In addition, GSK343 also induces apoptosis of EOC cells in 3D and significantly inhibits the invasion of EOC cells.


Synonyms

1H-Indazole-4-carboxamide, N-[(1,2-dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-
N-[(1,2-Dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxamide
1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxamide
GSK 343